Chimeric immune receptors (CIR) encompass tumor-or were constructed to include alternative extracellular spacer virus-specific ligands or antibodies fused to the signaling and transmembrane protein domains derived from memdomains of either the T cell receptor or Fc receptor. T cells bers of the immunoglobulin supergene family. The effect of expressing these receptors recapitulate the cytopathic these alternative extracellular protein domains on receptor effects mediated by the T cell receptor and allow the tarstability, antigen affinity and T cell activity was assessed. geting of tumor or virus infected cells in an MHC-indeWe demonstrate that modifying the extracellular protein pendent manner. With this technology, large numbers of T domains of the anti-HIV env CIRs significantly impacted cells with redirected target specificity can be generated. To receptor stability and substrate binding affinity and that define the structural features of recombinant CIRs required these effects, and not simply the level of cell surface for optimal function, a panel of five closely related CIRs expression, correlated most strongly with changes in CIRwith identical target specificity were generated. These mediated killing. These studies will aid in the rationale receptors recognized HIV env through the single chain Fv design of recombinant CIRs for the immunotherapy of viral (scFv) of an anti-gp120 antibody. These scFv-receptors infections, cancer and other diseases.
Introduction
Conventional T cell immunotherapy relies on the difficult and time-consuming isolation and expansion of antigenspecific T cells which are reintroduced into patients to effect an antitumor or antiviral response. To overcome these difficulties, several groups have described the genetic modification of T cells to express recombinant CIRs which mediate MHC-independent killing of target cells. These receptors comprise an extracellular antigen binding domain, derived from an antigen-specific antibody or ligand, coupled to an intracellular signaling domain derived either from the CD3 chain of the T cell receptor complex, [1] [2] [3] [4] [5] the Fc receptor (FcR) ␥ chain tumor [5] [6] [7] or more distal components of the T cell signal transduction pathway such as the syk molecule. 8 In this fashion, genemodified T cells can be redirected to recognize a broad assortment of tumor and viral antigens including HER-2/Neu (erb-B2), 3, 5 HIV env , 4 folate binding protein, 6 IgE 9 and TAG-72. 2 The scFv or ligand antigen binding domains in these CIRs must be coupled to the T cell receptor signaling moiety via a heterologous protein spacer domain to retain receptor function 10 or in certain receptors, even for receptor expression (D Smith, unpublished results). Most of the CIRs generated have employed the immunoglobulin hinge and constant regions as a heterologous protein spacer domain 1, 2, 4, 5, 7 although in the one comparative study of the impact of the length of the heterologous protein spacer domain on receptor expression and function, fragments of the CD4 or CD8 protein were employed. 3 The different heterologous protein spacer domains used in the various CIRs that we have generated have shown a tremendous impact on receptor expression and function (J McArthur, unpublished results). It is difficult, however, to assess the relative impact of these various spacers on CIR function using receptors that comprise different antigen binding domains. To determine systematically the optimal spacer domains for T cell function, five retroviral constructs were generated which encode CIRs that all recognize HIV env through the anti-gp120-specific scFv, 447D. 11, 12 The 447D scFv in each construct was linked via various heterologous protein spacer domains to the T cell receptor CD3 chain signaling domain. The heterologous protein spacer domains were selected from immunoglobulin supergene family members IgG1, CD4, CD7 and CD8. The sixth CIR is the previously described ligand-based receptor CD4-that, like the 447D scFv-receptors, also binds HIV env gp120. 4 A comparative analysis of these constructs at the level of protein expression, receptor stability, target protein affinity and T cell function revealed several parameters in addition to receptor expression, which correlated with optimal activity. We further show that scFv-receptors that incorporated the IgG1 CH 2 CH 3 or CD7 heterologous protein spacer domains demonstrated the greatest cytokine secretion and cytolytic activity against HIV env -positive target cells. generated with minimal expansion of the T cells. The findings of this report are summarized in Table 1 .
T cell expression of the scFv-CIRs
We determined cell surface expression by FACS analysis, and total protein expression by Western analysis. FACS analysis was carried out using a biotinylated HIV env gp120 protein (Figure 1) . The recombinant gp120 utilized in these experiments corresponds to the HIV IIIb isolate recognized by the 447D scFv-and CD4-CIRs. By FACS analysis the highest receptor surface expression was observed with the scFv-CH 2 CH 3 -and scFv-CD8-receptors. The scFv-CD7-receptor was expressed at lower levels followed by the scFv-V3V4-and scFv-CH 3 -receptors which were barely detected by FACS. T cell expression of the control CD4-receptor was comparable with the scFv-CD7-receptor and lower than the scFv-CH 2 CH 3 -receptor. Total protein expression was determined by Western analysis using a monoclonal antibody that recognized the common CD3 signaling domain present in all of the scFv-constructs (data not shown).
The Western analysis was in agreement with the FACS data with the exception of the scFv-V3V4-CIR which was expressed at higher levels than would have been predicted from the FACS analysis.
Southern analysis of transduced T cell DNA A trivial explanation for the different levels of surface expression of the various CIRs was unequal T cell transduction efficiencies with the various scFv-CIR retroviruses. To address this, Southern analysis of SalI digested, genomic DNA from the transduced T cells, utilizing a 300 bp probe specific for the common CD3 sequence, was performed to determine the relative integrated CIR transgene copy numbers. In each case a 7-kb band corresponding to the endogenous CD3 gene ( Figure 2 , designated CD3) and a smaller band (approximately 700 bp) corresponding to the CIR sequence were detected ( Figure 2 , designated CIR). In this analysis the endogenous CD3 gene acts as an internal control for the amount of DNA loaded in each lane. The band corresponding to the CIR was less intense than endogenous CD3 gene in all CIR gene-modified T cells, indicating that the CIR constructs were present at a copy number of less than two copies per cell. This is not unexpected as the Southern analysis was performed on T cell populations containing both transduced and nontransduced T cells. The CIR gene copy was comparable for most of the scFv-receptors, when the variability in DNA loading is accounted for. The one exception was the scFv-CH 3 -receptor, which demonstrated low expression by FACS, and was barely detected in this Southern analysis. Conversely, the Southern analysis demonstrated that the low surface expression of the scFv-V3V4-receptor observed by FACS, did not result from poor transduction efficiencies of this construct. Similarly, the high surface expression of the CD4-, scFv-CH 2 CH 3 -, scFv-CD8-and scFv-CD7-receptors was not attributable to higher transduction efficiencies for these constructs.
Activity of CIR gene-modified T cells
The functionality of the scFv-CIR was determined both by measuring the cytolysis of HIV env expressing targets by CIR gene-modified T cells and the measurement of cytokines released by the CIR expressing T cells when cultured with HIV env -positive cells. A representative cytotoxicity assay is shown in Figure 3a . Although the levels of cytolytic activity showed some experimental variation, the relative potency of the different CIRs was consistent from experiment to experiment. CD4-T cells invariably demonstrated the greatest lytic activity followed by the scFv-based receptors. The two scFv-based receptors encompassing the CD7 and Ig(CH2CH3) spacer domains were the most active (closed diamonds and triangles, respectively). No significant lysis of env-negative targets was observed by any of the CIR gene-modified T cells (Figure 3a controls, open symbols). When the lysis of target cells by CIR gene-modified T cells from numerous cytotoxicity assays was calculated as a percentage of the lysis obtained with the CD4-T cells, a hierarchy of scFv-CIR activity is observed ( Figure 3b ). The scFv-CH2CH3-and scFv-CD7-CIRs consistently demonstrated the greatest cytolytic activity followed by the scFv-CD8-, scFv-CH3-and scFv-V3V4-CIRs. A similar hierarchy was observed when the cytokine production of CIR gene-
Figure 3 Representative analysis of the cytotoxicity mediated by different CIRs. (a) Increasing numbers of transduced T cells expressing the CIRs were incubated with HIV env expressing target cells (closed symbols) or matched HIV env negative targets (open symbols) and cells cytotoxic activity was assessed by
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Cr release. The T cells in this assay were transduced with CD4-(closed squares), scFv-CD7-(closed diamonds), scFv-CH 2 CH 3 -(closed triangles) or scFv-CD8-(closed circles). Target cell lysis by mock-transduced T cells was not observed (closed squares). (b) Lysis of target cells by CIR gene-modified T cells from all of the cytotoxicity assays was then calculated as a percentage of the lysis obtained with the CD4-T cells (100%) and these numbers are shown in the bar graph along with the experimental variability. (c) Cytokine secretion by CIR gene-modified T cells cultured in the presence of target cells for 24 h was determined at an effector to target ratio of 10:1. GM-CSF secretion is shown in black, INF-␥ secretion is shown in white, and TNF-␣ secretion is shown in gray. The levels of cytokines produced by nontransduced T cells were: GM-CSF (6.2 pg/ml), INF-␥ (nondetected) and TNF-␣ (1.2 pg/ml).
modified T cells in the presence of targets was determined for lysis at an effector to target ratio of 1 ( Figure  3c ).
While the cytokine and cytolytic activity data were consistent with each other, these results were inconsistent with the surface expression of the anti-HIV env CIRs. In particular, the scFv-CD8-was expressed at higher levels than the scFv-CD7-and yet its activity did not reflect this. Conversely, the cytolytic activity and cytokine secretion by CD4-CIR gene-modified T cells were greater than the scFv-CH2CH3-expressing T cells while surface expression of the CD4-CIR was lower. To establish the basis of the greater activity of the CD4-CIR, the relative receptor stability and ligand affinity of the CD4-and several of the scFv-CIRs were determined.
Stability of CIRs in transduced T cells
To determine the stability of the CIRs, cell lysates were prepared from gene-modified T cells pulsed for 1 h with 35 S methionine-cysteine and then incubated in media containing unlabeled methionine-cysteine for increasing amounts of time. The scFv-V 3 V 4 and CD4-CIRs were immunoprecipitated with an anti-CD3 antibody and the scFv-CD7-CIR immunoprecipitated with an anti-CD7 antibody (Figure 4 ). Radiolabeled CD4-protein increased over the first 3 h and was detected up to 20 h following the pulse (Figure 4 , center panel). The reason for the initial increase in labeled protein is unknown but may result from a sequestration of labeled protein. The endogenous CD3 chain was also immunoprecipitated with this antibody, although it was labeled less intensely. Interestingly, the radiolabeled endogenous CD3 protein was also observed for 20 h. Large amounts of the scFv-V3V4-protein were labeled during the pulse period, however, the amount of labeled protein decreased by more than 50% after only 1 h and was undetectable after 6 h (Figure 4) . Similarly, the scFv-CD7-CIR was extensively labeled, but unlike scFv-V3V4-, the level of radiolabeled scFv-CD7-receptor remained high beyond 1 h and was still detected 20 h following the pulse, albeit at low levels. The higher background observed with the CD7-is likely the result of using a polyclonal anti-sera. Obviously, one factor contributing to the high activity of the CD4-CIR is the great stability of this receptor even compared with potent scFv-CD7-CIR. Conversely, the rapid turnover of the scFv-V3V4-CIR may be the reason for the poor expression and function.
CIR binding affinity for HIV env gp120 target protein The binding affinity of the different CIRs for the target HIV env gp120 was assessed using a FACS-based competitive binding assay. T cells expressing the CIRs were incubated with recombinant biotinylated HIV env gp120 in the presence of increasing amounts of a competing peptide encoded by HIV env gp120 ( Figure 5 ). HIV gp120 is a 477 amino acid (aa) protein which contains five hypervariable domains designated V1 to V5. The V3 loop of the gp120 HIV IIIb isolate contains the epitope GPGR (aa 317-320) recognized by the 447D antibody 11 while the DPE sequence (aa 373-375) is the point of interaction with CD4.
14 Peptides that included one of these sequences or an irrelevant sequence from HIV env were employed in a FACS-based competitive binding assay to assess the affinity of the scFv-and CD4-CIRs for HIV env .
As expected, the GPGR peptide inhibited the binding of gp120 to either of the 447D-based CIR, scFv-CD7-or scFv-CH2CH3-( Figure 5 , left and center panels). The GPGR peptide did not, however, impact the binding of gp120 to CD4-even at the highest peptide concentrations used (10 g) ( Figure 5, right panel) . An overlapping HIV env peptide (aa 312-320) showed a similar inhibition pattern while the irrelevant HIV env derived peptide (aa 487-509) did not effect the binding of any of the CIR tested. The scFv-CD7-was most susceptible to peptide competition, with less than 0.5 g of peptide producing the dramatic decrease in HIV env binding as shown in Figure 5 . The scFv-CH2CH3-CIR required five-fold more peptide to reduce binding to a similar extent (the
Figure 4 Assessment of the stability of CIRs by pulse-chase analysis of metabolically labeled T cells. T cells expressing CIRs were labeled with 35 S and the turnover of protein assessed by immunoprecipitating labeled proteins over the times shown. The same antibody used for Western analysis was used here for scFv-V 3 V 4 -and CD4-. For scFv-CD7-, an anti-CD7 antibody was utilized.
Figure 5 Assessment of the target binding activity of CIRs with a competitive binding assay. T cells expressing CIRs were incubated with 1 g of recombinant biotinylated HIV env gp120 and various concentrations of competing peptide for 3 h at room temperature. Shown is the inhibition obtained with the peptide encompassing the 447D binding site in HIV env at a concentration of 0.5 g/ml. The amount of bound gp120 was measured by FACS detection using a streptavidin-FITC gp120 reagent.
inhibition observed with 0.5 g of peptide is shown). Significantly, the binding of CD4-to gp120 was unaffected by all peptides, including several that encompassed the CD4 binding site in gp120 (aa 373-375), even at concentrations of up to 10 g (data not shown). These results indicate that while there is a significant difference in antigen affinity of the antigen binding domains of these receptors, the heterologous protein spacer domains can also have an immense impact on the CIR-antigen affinity.
Discussion
CIRs offer the opportunity to generate large numbers of antigen-specific T cells for the treatment of viral and malignant diseases. Similar to all receptors, the CIRs must be able to perform two functions, ligand binding and transmission of the appropriate signal. The appropriate interaction of the protein domains responsible for these distinct functions is critical for receptor function. In creating novel CIRs, it is easy to view the heterologous spacer domain as simply a linker joining the ligand binding and signaling domains. Earlier studies suggested that while a heterologous spacer domain was necessary, the nature of the heterologous spacer domain was irrelevant to the function of the receptor. 3 We sought to determine if this was the case or whether there were heterologous spacer domains that offered clear advantages over others in the context of CIR expression and function. To ascertain this, five novel HIV env -specific scFv-based CIRs were generated with identical ligand binding and signaling domains, but with alternative heterologous spacer domains. These related scFv-CIRs were introduced into human T cells by retrovirus-mediated transduction and their expression, stability, ligand affinity and ability to induce T cell-mediated cytolysis and cytokine production assessed. Although all CIRs mediated detectable antigenspecific target cell lysis and cytokine release, a clear functional hierarchy was observed. The reasons for this hierarchy were diverse. The low expression of the scFv-CH 3 -and scFv-V3V4-CIRs was the result of the poor transduction efficiency in the case of the scFv-CH 3 -, and a rapid turnover rate in the case of the scFv-V3V4-. Interestingly, the CD4-CIR, which exhibited good surface expression, incorporates the same V3V4 stalk domain, and yet has a slow turnover rate.
The CD4-CIR was the most active of the anti-HIV envspecific CIR examined. When the most active of the five scFv-based HIV env -specific CIRs, scFv-CH 2 CH 3 -and scFv-CD7-, were compared with the CD4-, disparities were observed both at the level of receptor stability and ligand affinity. The turnover of the scFv-CD7-CIR was intermediate between the poorly expressed scFv-V3V4-CIR and the stable CD4-CIR. Interestingly, when the ligand affinities of scFv-CD7-were compared with the scFv-CH 2 CH 3 -and CD4-CIRs, the scFv-CD7-interaction with HIV env easily competed with the peptide encoding the HIV env binding site of the 447D scFv. This is to be contrasted with the affinity of scFv-CH 2 CH 3 -for HIV env which required five-fold higher levels of the peptide encoding the HIV env binding site of 447D to compete with the binding of the intact HIV env protein. A series of peptides that encompassed the HIV env binding site of CD4 were unable to prevent the binding of the CD4-CIR to the HIV env protein.
All experiments presented here were carried out using unselected populations of CIR-transduced T cells, rather than isolated clones. This has several important consequences for the biology of the gene-modified T cells, the foremost being that these cells are resistant to T cell dysfunction induced by engagement of the CIR of T cells that are subjected to long-term culture in high IL-2 (J McArthur et al, unpublished results). In addition, unlike drugselected clones, the results obtained with these populations of T cells are less sensitive to position effects of the retroviral integration which averages out the influence of the site of virus integration into the genome on CIR protein expression levels. Our data illustrate how the heterologous spacer domains can alter CIR function through reduced receptor stability or ligand affinity. These data further suggest that the CD7 and IgG CH 2 CH 3 are the optimal heterologous spacer domains for scFv--based CIRs of the type described here. It is our hope that these studies will aid in the development of further CIRs for the treatment of human disease.
Materials and methods
Receptor construction
The scFv-CH 2 CH 3 -single chain antibody chimeric immune receptor used in these studies, comprises the scFv domains of the HIV env gp120-specific 447D antibody: V signal sequence, V variable domain (residues 1-107), the 14 amino acid L212 linker (GSTSGSGKSSEGKG), 15 VH variable domain (residues 1-113), linked to the hinge and Fc region of the human IgG2 heavy chain (residues 226-447). These were linked to the CD3 intracellular signaling domains (residues 31-142) through the 18 residue IgG3 M1 membrane hinge and the CD4 transmembrane domain (residues 372-395). The CD8 and CD7 spacer domains in the scFv-CD8-and scFv-CD7-CIRs, replace the IgG1 CH 2 CH 3 , IgG3 M1 membrane hinge and the CD4 transmembrane domains, with residues 105-165 of the mature CD8 protein and 145-180 (APPR%SALP) of the mature CD7 protein. The V3V4 spacer domain in the scFv-V3V4-CIR, replace the IgG1 CH 2 CH 3 and IgG3 M1 membrane hinge, with residues 131-395 of the mature CD4 protein. The CD4-molecule 4 contains the complete variable domains and the transmembrane domain of human CD4 (residues 1-372 of the mature CD4 protein) attached to the CD3 domain.
Cell lines and antibodies used TSA cells were maintained in DMEM supplemented with l-glutamine and penicillin-streptomycin. 293-HIV env gp120 transfectants 4 were maintained in the same media as TSA cells supplemented with 2 mg/ml G418. Anti-CD3 antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA), and alkaline phosphataseconjugated goat anti-mouse immunoglobulin serum and rabbit anti-mouse immunoglobulin serum were purchased from Dako (Carpenteria, CA, USA). Polyclonal anti-CD7 antiserum was purchased from Pharmingen (San Diego, CA, USA).
Generation of viral stock supernatants
Two days before transfection, TSA cells were seeded at 5 × 10 5 cells per 10 cm culture dishes. The TSA cells were transfected by the calcium phosphate coprecipitation method with 10 g of retroviral vector pRT43.2 encoding the CIR of interest and 5 g of packaging plasmid. The medium was changed 24 h following transfection and culture supernatants were harvested and filtered 24 h later.
Culture and transduction of human T cells PBMC from buffy coats were diluted 1:4 with PBS (Ca/Mg free + 1 mm EDTA) and 20 ml of diluted blood layered on top of 14 ml of Ficoll and spun at 740 g for 30 min. The interface was collected and diluted again 1:4 with PBS (Ca/Mg free), spun at 350 g for 5 min and the pellet washed twice more with PBS. The Ficoll-purified PBMC were resuspended at 10 7 cells/ml in T cell medium (TCM) (1:1 AIM-V and RPMI with Hepes, sodium pyruvate, glutamine, penicillin-streptomycin and 10% human serum). The PBMC were transferred to a T175 flask at 40 ml per flask and incubated for 1-1.5 h at 37°C to remove monocytes. The non-adherent cells were resuspended at 3 × 10 6 cells/ml and added to anti-CD3 and anti-CD28 antibodycoated Dynal beads at a density of three cells per bead in TCM. The T cells were stimulated with the anti-CD3/CD28 beads for 48 h at 37°C. On day 2 the beads were removed from cells magnetically. The PBMC were then spun down and resuspended into TCM with 100 IU/ml IL-2 at 1 × 10 6 cells/ml. Twenty-four hours later the T cells were spun down and resuspended at 10 6 cells/ml TCM with 100 IU/ml IL-2. The T cells were added to an equal volume of supernatant containing the CIR encoding retrovirus and supplemented with IL-2 and polybrene (100 IU/ml and 2 g/ml final concentration) to bring the cell density to 0.5 × 10 6 cells/ml. Following a 24 h incubation at 37°C, half the medium was removed and replaced with an equivalent amount of the vector containing medium. This step was repeated 48 h later. On day 6 the cells were removed from the transduction mix and resuspended in TCM with IL-2 at 10 6 cells/ml. The culture was then split every 2-3 days to 10 6 cells/ml for an additional 4-10 days.
Southern analysis
Twenty milligrams of DNA, isolated by standard methods, were digested with SalI and electrophoreses using a 0.7% agar gel. DNA was transferred to nitrocellulose by capillary action and blocked and probed by standard methods. The DNA probe was derived by PCR and corresponds to 300 bp of the CD3 sequence common to all constructs. The probe was labeled by random priming methodology.
Western blot analysis
For Western blot analysis, cells (2-5 × 10 5 per well) were resuspended in SDS sample buffer (0.125 m Tris.HCl, pH 6.8/1% SDS/1% 2-mercaptoethanol) before SDS/PAGE. Proteins were transferred on to nitrocellulose by standard methods and probed with a 1:1000 dilution of antibody. Bound antibodies were detected using alkaline phosphatase-conjugated secondary antibodies and standard detection reagents (Bio-Rad, Hercules, CA, USA).
Flow cytometry T cells (5 × 10
5 ) transduced with CIR constructs were assessed for surface expression by incubation with 3 g of biotinylated recombinant HIV env gp120 (Intracell, WA, USA) for 1 h at 4°C. The cells were washed three times in PBS-BSA (1%), and incubated with 100 l of a streptavidin-tricolor reagent (Caltag Laboratories, Burlingame, CA, USA) for 30 min at 4°C. The cells were washed as above and analyzed by FACS. To prevent endogenous CD4 from appearing on the FACS profiles, we gated and analyzed CIR expression on CD8 T cells.
Cytotoxicity assays
Cytotoxic activity was determined by a standard 4 h chromium release assay as follows: 1 × 10 6 293-env (HIV gp120) target cells were incubated with 100 Ci of 51 Cr in 100 l of media for 1 h at 37°C. The target cells were then washed extensively with media and 5 × 10 3 cells mixed with different numbers of T effector cells in a total volume of 200 l, in a round-bottom 96-well plate. Cells were pelleted following a 4 h incubation at 37°C, and 100 l of the resulting supernatant was used for counting in a gamma counter for assessment of 51 Cr release. The percentage of specific lysis was calculated from triplicate samples using the formula: [specific lysis = (released counts -spontaneous release counts) / (maximal release counts -spontaneous release counts) × 100]. Spontaneous release refers to the counts released by targets in the absence of effectors, and maximal release from targets was assessed by total lysis of targets by 100 l of 0.5% Triton X-100.
Metabolic radiolabeling and immunoprecipitation
For immunoprecipitation, 10 7 cells were metabolically labeled in 2 ml of RPMI (minus methionine, cysteine) with 300-500 Ci of 35 S methionine-cysteine (Translabel; Amersham, Bucks, UK) for 1 h. After washing in phosphate-buffered saline the cells were lysed in 1 ml of lysis buffer (1% Nonidet P-40/50 mm Tris.HCl, pH 7.4/150 mm NaCl/1 mm phenylmethylsulfonyl fluoride/ aprotinin (30 mg/ml)). Lysates were preabsorbed with 25 l of normal mouse serum and 100 l of protein Asepharose beads (Pharmacia, Piscataway, NJ, USA; 1:1 slurry in lysis buffer) for 1 h. Specific precipitation was carried out for 1 h with 10 g of monoclonal antibody, followed by 30 min incubation with 10 l of a rabbit antimouse immunoglobulin preparation (Dako). Precipitates were collected by incubation for 30 min with 100 l of protein A-sepharose slurry and centrifugation. After washing three times in lysis buffer containing 0.25% Nonidet P-40, the precipitates were resuspended in SDS/PAGE buffer and analyzed by SDS/PAGE. Gels were treated with salicylic acid before drying and exposure to film for 24 h.
Competitive binding assays 5 × 10 5 CIR expressing T cells were incubated with up to 1 g of biotinylated recombinant HIV env gp120 (Intracell, Seattle, WA, USA), and different concentrations of peptide for 3 h at room temperature. The cells were subsequently washed and the level of binding assessed by incubation with streptavidin-FITC and FACS analysis.
Cytokine assays 5 × 10 4 CIR T cells were incubated with 293-env cells at an effector to target ratio of 10:1 in a round-bottom 96-well plate for 4 h at 37°C and the media collected and spun at 322 g for 4 min. The supernatants were then stored at −80°C for future assaying with the R&D Systems (Minneapolis, MN, USA) cytokine kits for GM-CSF, IFN-␥, TNF-␣.
